Fig. 2: Subsequent treatments.
ST subsequent treatment, VEGFi vascular endothelial growth factor inhibitor, PARPi poly ADP-ribose polymerase inhibitors, PLD pegylated liposomial doxorubicin.
Fig. 2: Subsequent treatments. | British Journal of Cancer
ST subsequent treatment, VEGFi vascular endothelial growth factor inhibitor, PARPi poly ADP-ribose polymerase inhibitors, PLD pegylated liposomial doxorubicin.
